|[December 18, 2013]
Clinical Research Proves Efficacy of Canine Platelet Enhancement Therapy (C-PET) for Treatment of Osteoarthritis (OA) in Dogs
PORT WASHINGTON, N.Y. --(Business Wire)--
A randomized, controlled study organized by The Ohio State University
and Western University Health Sciences shows efficacy of autologous
platelet therapy for treatment of osteoarthritis (OA) in dogs using Pall's
Canine Platelet Enhancement Therapy (C-PETTM) kit. The
findings of the study, which were published in the November 1, 2013
issue of the Journal
of the American Veterinary Medical Association (JAVMA), offer
clinical relevance proving that a single intra-articular injection of
autologous platelets can significantly improve dogs with OA.
Pall's C-PET technology is a proven technique for treating canine osteoarthritis. (Photo: Business Wire)
The study evaluated 20 client-owned dogs diagnosed with OA in a single
joint. The dogs were randomly assigned to either a treatment group or a
control group. They weighed from 40 to 140 pounds, included a wide array
of breeds, and ranged in age from 1.5 to 8 years. Lameness of each dog
was assessed by their owners using the Hudson
Visual Analog Scale (HVAS). Pain was evaluated using the University
of Pennsylvania's Canine Brief Pain Inventory (CBPI). The objective
measurement of function and weight bearing was determined by the "gold
standard" force plate measurement of peak vertical force (PVF)1.
The results showed dogs that received C-PET platelet injections
significantly improved lameness scores, pain scores and PVF after 12
weeks, compared with pre-treatment values. In contrast, control dogs'
lameness scores, pain scores and PVF at week 12 were not significantly
different from pre-treatment values.
C-PET provides a minimally invasive treatment for OA in dogs. It is
safe, effective and convenient. The entire procedure requires about 30
minutes, as documented in the study. It is important to note that not
all platelet-rich plasma (PRP) preparation techniques are the same.
Therefore, the success or failure of a specific PRP product is not
necessarily predictive of all PRP preparations. Well-designed,
prospective, randomized, blinded (Level 1) clinical studies are needed
to carefully and comprehensively investigate the role of the various PRP
preparations. Pall's C-PET is the first platelet technique for treating
OA in dogs proven through an objective clinical study.
For more information on C-PET, please visit www.Pall.com/CPET.
About Pall Corporation
Pall Corporation (NYSE:PLL)
is a filtration, separation and purification leader providing solutions
to meet the critical fluid management needs of customers across the
broad spectrum of life sciences and industry. Pall works with customers
to advance health, safety and environmentally responsible technologies.
The company's engineered products enable process and product innovation
and minimize emissions and waste. Pall Corporation is an S&P 500 company
serving customers worldwide. Follow us on Twitter (News - Alert) @PallCorporation or
1 Force plate and computer analysis system, Kistler
Instrument Corp, Amherst, NY.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131218006455/en/
[ Back To Technology News's Homepage ]